DAMGO

Research use only, not for human use.

DAMGO is an opioid receptor agonist with the ability to affect the locomotive activity in rodents. Possible analgesic agent due to μ-opiod receptor interaction.

DAMGO is an opioid receptor agonist with the ability to affect the locomotive activity in rodents. Possible analgesic agent due to μ-opiod receptor interaction.

DAMGO (1-10 μM) significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression. DAMGO (1 μM) effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R I Na), i.e. PGE 2 (1 μM) can increase the TTX-R I Na peak by 103 % compared to 24.9 % with the addition of DAMGO.

DAMGO (i.v., 0.5-2 mg/kg) can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect.

——

MAPK/ERK Signaling

p38 MAPK

μ-opioid receptor

——

——

78123-71-4

513.6

C26H35N5O6

>98% (HPLC)

DMSO : 33.33 mg/mL. 64.90 mM;

Oc2ccc(C[C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO)cc2

——

(-20℃)

With Ice Pack

≥ 2 years